Search Results

Displaying Results 1-1 of 1 "'AROC'"
Making a selection with these dropdown will cause content on this page to change. News search result will update as each option is selected.
Complement 3 Glomerulopathy Market Set for Transformation: 4 Emerging Therapies Leading the Next Growth Phase | DelveInsight

Jul 16, 2026, 10:31 ET Complement 3 Glomerulopathy Market Set for Transformation: 4 Emerging Therapies Leading the Next Growth Phase | DelveInsight

of complement-mediated kidney diseases. The therapy is currently being evaluated in the Phase I/IIa first-in-human dose-escalation study (NCT05083364/AROC3-1001), which is assessing its safety, tolerability, pharmacokinetic profile, and pharmacodynamic effects in both healthy adult volunteers and patients

More news about: DelveInsight Business Research, LLP

Making a selection with these dropdown will cause content on this page to change. News search result will update as each option is selected.